



**CRAIG GRANOWITZ, MD, PHD**  
**SVP, CHIEF MEDICAL OFFICER, AMARIN PHARMA INC.**

Dr. Craig Granowitz is the Chief Medical Officer at Amarin Pharma Inc. who provides strategic and operational leadership across multiple functional areas including medical affairs, drug safety, post-marketing interventional and non-interventional studies, patient and professional society interactions and medical communication. He is also a member of the Amarin Executive Team.

Dr. Granowitz was actively involved with, and was an author on the REDUCE IT trial, a landmark study of icosapent ethyl (VASCEPA) which showed unprecedented reduction in cardiovascular events compared to placebo in high risk patients which was published in the *New England Journal of Medicine* and presented as a “late-breaker” at the 2018 American Heart Association Annual Meeting.

For almost two decades, Dr. Granowitz has held several commercial and medical roles at multi-national pharmaceutical companies, managing the portfolios of leading cardiovascular products. Prior to joining Amarin, he was Senior Vice President and Head of Global Medical Affairs, Global Human Health at Merck, where he developed and implemented a new global Medical Affairs organization following Merck’s merger with Schering-Plough. In this capacity, among his many achievements, Dr. Granowitz provided critical medical affairs support in the run-up to and read-out of Merck’s cardiovascular outcomes study, IMPROVE-IT. From 2003 to 2008, he was Group Vice President, Head of Global Medical Affairs for Schering-Plough. His work at Schering-Plough, and later Merck, was critical to the growth and success of their global medical affairs organization that spanned multiple therapeutic areas and operated in more than 80 countries worldwide. Prior to leading the Medical Affairs department at Schering-Plough, Dr. Granowitz spent more than 15 years in sales and marketing roles for their US and Global businesses; starting as a sales representative and rising to Senior Vice President of a \$2.5 Billion Virology Business Unit.

Earlier in his career, he co-founded Proliance Pharmaceuticals, a venture capital-backed pharmaceutical development and finance management start-up company.

Dr. Granowitz is a well-respected expert in cardiovascular health and has authored/published over 40 peer-review abstract and manuscripts in many journals and publications in the area of cardiology since joining Amarin, including *The Journal of the American College of Cardiology*, *American Association of Clinical Endocrinologist*, *Academy of Managed Care Pharmacy*, *American Diabetes Association*, *American Heart Association*, *American Society for Preventative Cardiology*, *European Society of Cardiology*, *Heart Failure Society of America*, *International Society for Pharmacoeconomics and Outcomes Research*, *National Kidney Foundation* and the *National Lipid Association*.

He is sought after by various organizations as an expert speaker on the topic of cardiovascular diseases and risk factors, and has built strong relationships with other experts and thought leaders in his field.

Dr. Granowitz currently serves on several non-profit and educational organizations, including the American Heart Association (New York Chapter), American Associates Ben-Gurion University of the Negev, Columbia University Vagelos College of Physicians and Surgeons, and the Rabbinical College of America-Lubavitch in Morristown, New Jersey.